| Primary | The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. | Posted | | Number | | Percentage of participants | | baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| | | Title | Denominators | Categories |
|---|
| | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | | | | | Percentage | 75.8 | | | 2-Sided | 95 | 73.0 | 78.5 | | | | | Superiority or Other | | |
|
| Secondary | The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. | Posted | | Number | | Percentage of participants | | baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. | Posted | | Number | | Percentage of participants | | Baseline to 12 and 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those participants who have a baseline and at lease 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Mean | Standard Error | mm Hg | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Mean | Standard Error | mm Hg | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks | Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. | Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 12 week ABPM data. | Posted | | Number | | Percentage of participants | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks | Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. | Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 20 week ABPM data. | Posted | | Number | | Percentage of participants | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks | Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m. | Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 12 week ABPM data. | Posted | | Number | | Percentage of participants | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks | Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m. | Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 20 week ABPM data. | Posted | | Number | | Percentage of participants | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks | Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. | Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 12 week ABPM data. | Posted | | Number | | Percentage of participants | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks | Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. | Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 20 week ABPM data. | Posted | | Number | | Percentage of participants | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values | Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. | Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 12 week ABPM data. | Posted | | Mean | Standard Error | mm Hg | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values | Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. | Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 20 week ABPM data. | Posted | | Mean | Standard Error | mm Hg | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those African American/Black participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those African American/Black participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those African American/Black participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those Asian participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those Asian participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those Asian participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those Asian participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those Hispanic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those Hispanic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those Hispanic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those Hispanic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those elderly participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. Elderly is defined as greater than or = to 65 years of age. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those elderly participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. Elderly is defined as greater than or = to 65 years of age. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those elderly participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. Elderly is defined as greater than or = to 65 years of age. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those elderly participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. Elderly is defined as greater than or = to 65 years of age. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those type 2 diabetic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those type 2 diabetic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those type 2 diabetic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those type 2 diabetic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those obese participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. Obesity is defined as Body Mass Index ≥30 kg/m2 | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those obese participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. Obesity is defined as Body Mass Index ≥30 kg/m2 | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those obese participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. Obesity is defined as Body Mass Index ≥30 kg/m2. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | The analysis population consists of those obese participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. Obesity is defined as Body Mass Index ≥30 kg/m2 | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | Subjects with metabolic syndrome (MS) who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. The number may vary due to missing data and the number of dropouts. MS is defined using waist size,and triglyceride, cholesterol, blood pressure, and body mass index values. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks | | Subjects with metabolic syndrome (MS) who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. The number may vary due to missing data and the number of dropouts. MS is defined using waist size,and triglyceride, cholesterol, blood pressure, and body mass index values. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | Subjects with metabolic syndrome (MS) who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. The number may vary due to missing data and the number of dropouts. MS is defined using waist size,and triglyceride, cholesterol, blood pressure, and body mass index values. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks | | Subjects with metabolic syndrome (MS) who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. The number may vary due to missing data and the number of dropouts. MS is defined using waist size,and triglyceride, cholesterol, blood pressure, and body mass index values. | Posted | | Number | | Percentage of Participants | | Baseline to 4, 8, 12, 16, 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks | | Participants previously on a Dihydropyridine Calcium Channel Blocker who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks | | Participants previously on a Dihydropyridine Calcium Channel Blocker who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks | | Participants previously on a diuretic who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| | |
| Secondary | Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks | | Participants previously on a diuretic who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| | |
| Secondary | Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks | | Participants previously on an angiotensin converting enzyme inhibitor who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks | | Participants previously on an angiotensin converting enzyme inhibitor who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks | | Participants previously on an angiotensin II receptor blocker who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks | | Participants previously on an angiotensin II receptor blocker who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks | | Participants previously on an beta blocker who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks | | Participants previously on an beta blocker who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks | | Participants previously on a Nondihydropyridine Calcium Channel Blocker who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |
| Secondary | Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks | | Participants previously on a Nondihydropyridine Calcium Channel Blocker who have received at least one dose of study medication and who have a baseline value. | Posted | | Number | | Percentage of participants | | Baseline to 20 weeks | | | | ID | Title | Description |
|---|
| OG000 | Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks |
| |